C4U Corporation (“C4U”) and Minaris Advanced Therapies (“Minaris”) are pleased to announce that we have recently signed a Memorandum of Understanding (“MOU”) for certain collaboration.
C4U is promoting the development of novel therapies for various diseases, including genetic diseases, utilizing CRISPR-Cas3, a unique genome editing technology, both in-house and in collaboration with other companies. Furthermore, C4U is developing its technology platform for a variety of applications in the medical field as well as a wide range of other industrial fields.
Minaris is a leading global contract development and manufacturing organization (CDMO) specializing in regenerative medicine and advanced therapy products, with operations in North America (U.S.), Europe (Germany and the U.K.), and Asia (Japan). With over 25 years of experience, Minaris has provided valuable process development expertise and clinical/commercial manufacturing services to its clients, delivering technical know-how and innovation across the globe.
With the conclusion of this MOU, C4U and Minaris will aim to create new value in the areas of regenerative medicine and gene/cell therapy through collaboration in promotional activities and customer introductions by leveraging our respective technologies, knowledge, and networks.
About C4U Corporation
About C4U Corporation
C4U is a privately held biotech company based in Osaka, Japan, and is focused on the development of safe and efficient gene therapies utilizing its proprietary next generation CRISPR-Cas3 gene editing platform. In comparison to the CRISPR-Cas9 platform, CRISPR-Cas3 presents the distinct benefits of: 1) no off-target by the higher selectivity of deletion site (improved safety); 2) efficient knockouts by the larger deletion of gene sequences; and 3) an entirely independent patent portfolio. C4U has been granted a worldwide exclusive license to CRISPR-Cas3 by Osaka University for use in eukaryotic cells thus simplifying sublicensing transactions which is in sharp contrast to the complex and heavily litigated CRISPR-Cas9 patent landscape.
URL：https://www.crispr4u.jp/en/
About Minaris Advanced Therapies
Minaris is the Japanese subsidiary of Minaris Advanced Therapies, a global CDMO specializing in regenerative medicine and advanced therapy products. With over 25 years of experience, Minaris Advanced Therapies operates more than 60,000 square meters of facilities across the U.S., Europe, and Asia, and has manufactured and released over 7,500 GMP batches. Through its global network, the company provides comprehensive support from early-stage development to clinical trials and commercial manufacturing. By combining scientific expertise with manufacturing and testing services, Minaris aims to deliver safe and effective therapies to patients more quickly and efficiently.
URL: https://minaris.com
